Clinical Trial Update: A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention [Phase 4]

View source ↗

Summary

Clinical trial update reporting results from a Phase 4 study of satralizumab in neuromyelitis optica spectrum disorder, with the trial terminated and results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica Spectrum Disorder

Drugs mentioned

• Satralizumab (satralizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Neuromyelitis Optica Spectrum Disorder, NMOSD | Phase 4 | Status: TERMINATED | Results posted: 2025-01-22